CD8B-binding polypeptides

{
  "publication_number": "US2026102527A1",
  "country": "US",
  "kind": "A1",
  "title": "CD8B-binding polypeptides",
  "abstract": "The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and cynomolgus CD8b protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer.",
  "claims": [
    "1. A polypeptide binding to human CD8b, wherein the amino acid sequence of the polypeptide is comprising a CDR1 region, a CDR2 region, and a CDR3 region, wherein the CDR1, CDR2 and CDR3 regions are selected from those CDR1, CDR2 and CDR3 regions as present in an immunoglobulin variable domain (IVD) defined by SEQ ID NOs:1, 2 or 3 and as determined by the Kabat, Chothia, Martin, or IMTG method. 2. The polypeptide according to claim 1 wherein the CDR1 region is chosen from SEQ ID NO: 12 and 13, the CDR2 region is chosen from SEQ ID NOs: 14 and 9, and the CDR3 region is chosen from SEQ ID NOs: 10 and 11. 3. The polypeptide according to claim 1 further comprising at least an FR1, FR2, FR3, or FR4 region as present in an IVD. 4. The polypeptide according to claim 3 wherein the FR1 region is defined by SEQ ID NO: 19, the FR2 region is defined by SEQ ID NO:24, the FR3 region is defined by SEQ ID NO:29, and the FR4 region is defined by SEQ ID NQ:30. 5. The polypeptide according to claim 1 wherein the CDR and/or FR regions are humanized and/or the IVD is humanized. 6. The polypeptide according to claim 1 which is further comprising a functional moiety. 7. The polypeptide according to claim 6 wherein the functional moiety is a His-tag or a peptide motif recognized by a peptide ligase. 8. The polypeptide according to claim 6 wherein the functional moiety is a detectable moiety. 9. The polypeptide according to claim 8 wherein the detectable moiety is linked to a specific site comprised in the polypeptide. 10. An isolated nucleic acid encoding a polypeptide according to claim 1. 11. A vector comprising the nucleic acid according to claim 10. 12. A host cell expressing a polypeptide according to claim 1, or comprising a nucleic acid encoding said polypeptide, or comprising a vector comprising said nucleic acid. 13. A pharmaceutical composition comprising a polypeptide according to claim 1. 14. A method of diagnosis, said method comprising administration of the polypeptide according to claim 1, or a pharmaceutical composition comprising said polypeptide to a subject. 15. A method for producing a polypeptide according to claim 1 comprising: expressing the polypeptide in a host cell comprising a nucleic acid encoding the polypeptide or a vector comprising said nucleic acid, or synthetic manufacture of the polypeptide; purifying the expressed or manufactured polypeptide; and optionally, coupling a detectable moiety to the purified polypeptide. 16. A method of therapy monitoring, said method comprising administration of the polypeptide according to claim 1, or a pharmaceutical composition comprising said polypeptide to a subject. 17. A method of surgical resection of a tumor, said method comprising administration of the polypeptide according to claim 1, or a pharmaceutical composition comprising said polypeptide, to a subject, optionally wherein the polypeptide comprises a detectable moiety and assists in delineating the tumor during resection. 18. An imaging agent comprising the polypeptide according to claim 1, or a pharmaceutical composition comprising said polypeptide."
  ],
  "description_excerpt": "The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement n o 831514. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA.\n\nThe invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and cynomolgus CD8b protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer.\n\nImmunomodulating agents, and immune checkpoint inhibitors (ICIs) in particular, have revolutionized cancer treatment. Although highly effective in a subset of cancers and cancer patients, ICIs remain ineffective in a relative large fraction of cancers and cancer patients. Many efforts are now devoted to understanding the underlying inferior response or non-response to ICI therapy, and to finding ways to break poor response to ICI therapy. Prediction or follow-up of response of a cancer patient to ICI therapy, or to therapy including an immunomodulating agent in general, prior to or during the therapy would be ideal both for the patient (in terms of helping in finding the best possible therapy) and in socio-economic terms (helping in optimal allocation of available healthcare funding). Therapy prediction or follow up, using invasive methods such as biopsies or blood biomarkers, has, however, so far proven to be difficult as they do not provide a complete overview of the tumor micro-environment and/or lack spatial information.",
  "cpc": [
    "A61K 51/1027",
    "A61K 2039/505",
    "A61K 2123/00",
    "C07K 1/1077",
    "C07K 16/2815",
    "C07K 2317/565",
    "C07K 2317/567",
    "C07K 2317/569",
    "C07K 2317/92",
    "C07K 2317/94"
  ],
  "assignees": [
    "Vrije Universiteit Brussel VUB"
  ],
  "inventors": [
    "Jo Van Ginderachter",
    "Geert Raes",
    "Cécile VINCKE",
    "Nick Devoogdt",
    "Timo DE GROOF",
    "Yoline LAUWERS"
  ],
  "filing_date": "2024-01-26",
  "publication_date": "2026-04-16",
  "priority_date": "2023-01-27",
  "application_number": "US-202419151092-A",
  "cited_by_count": 0
}